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Objective: Right ventricular hypertrophy and subsequent dysfunction is common in patients with congenital
heart defects, but the molecular mechanisms underlying change from adaptive hypertrophy to dysfunction remain
elusive. We used the novel technique of proteomics to characterize protein changes in right ventricular myocar-
dium in a neonatal model of right ventricular hypertrophy and early dysfunction.
Methods: Twelve neonatal piglets were equally randomized to pulmonary artery banding (PAB group), or sham
operation (thoracotomy without banding). After 4 weeks, right ventricular morphology and function were as-
sessed in vivo using magnetic resonance imaging. Animals were humanely killed. Proteomics of right ventricular
myocardium was performed. Purified right ventricular proteins were separated by 2-dimensional difference gel
electrophoresis using fluorescent cyanine dyes. After gel imaging, software analysis revealed protein spots dif-
ferentially expressed between the 2 groups; these spots were excised and identified by mass spectrometry.
Results: On magnetic resonance imaging, animals with pulmonary artery banding demonstrated significant right
ventricular hypertrophy, cavity dilatation, and mild systolic impairment (right ventricular ejection fraction 39.8%
 15% vs 56.7%  10% controls; P< .05). Right ventricular free wall mass on harvest confirmed right ven-
tricular hypertrophy. Proteomic analysis revealed 18 proteins that were significantly differentially expressed: 5
structural proteins, 6 metabolic enzymes, 2 stress proteins, and 5 miscellaneous proteins. Expression of calsar-
cin-1 and vinculin was increased, as were certain metabolic enzymes, although F1-ATPase b-chain and heat shock
protein 70 decreased.
Conclusions: This is the first study characterizing right ventricular protein changes in a large animal model spe-
cifically capturing the change from compensated to maladaptive hypertrophy. These findings can guide future work
at elucidating the mechanisms in the pathophysiology of neonatal right ventricular hypertrophy and dysfunction.
Congenital Heart Disease Sheikh et alHypertrophy of the right ventricle (RV) and its subsequent
dysfunction is a problem commonly encountered in complex
congenital cardiac defects or as sequelae to surgical correction.
RV subjected to pressure overload will adapt by undergoing
hypertrophy while still maintaining function, a state of com-
pensated or adaptive hypertrophy. With continuing abnormal
loading conditions, failure will ensue, a state known as decom-
pensated or maladaptive hypertrophy. Major morbidity and
mortality may result. Research in this area has mainly focused
on the left ventricle (LV); however, RV function is an impor-
tant indicator of long-term prognosis after surgical correction.1
The molecular mechanisms underlying the pathophysiologic
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elusive. Studies examining changes at the protein level have
used models of compensated RV hypertrophy.2,3
Proteomics is a rapidly evolving set of technologies that
allows protein expression to be examined globally in any
given system. By use of 2-dimensional gel electrophoresis
and appropriate protein labeling, thousands of proteins can
be resolved and relative protein abundances determined.
Proteins whose levels of expression are found to change in
the experimental or disease states can be excised from gels
and, through sensitive and accurate mass spectrometric anal-
ysis, be identified.4 Proteins that have never been previously
characterized may, in this way, be discerned.5 Differential
gel electrophoresis is a form of proteomic analysis that
uses covalent labeling of proteins with 3 fluorescent cyanine
ester protein dyes (Cy2, Cy3, and Cy5), which are detected
by their independent excitation and emission spectra. This
allows experimental and control animal samples to be frac-
tionated concurrently, along with an internal control, on
each gel. As well as being highly sensitive, the use of the in-
ternal control eliminates intergel variations and allows gels
to be standardized accurately to one other, thereby greatly
enhancing statistical accuracy.6
Using differential gel electrophoresis proteomic analysis,
we sought to determine the protein changes that occur inurgery c May 2009




FA ¼ flip angle
FOV ¼ field of view
HASTE ¼ half-Fourier acquisition single-shot
turbo spin-echo
HSF-1 ¼ heat shock transcription factor-1
HSP ¼ heat shock protein
LV ¼ left ventricle
MALDI ¼ matrix-assisted laser
desorption/ionization
MRI ¼ magnetic resonance image (imaging)
MS ¼ mass spectrometry
PA ¼ pulmonary artery
PAB ¼ pulmonary artery band (banding)
RV ¼ right ventricle
ST ¼ slice thickness
TE ¼ echo time
TOF ¼ time of flight
TR ¼ repetition time
a neonatal large animal model of RV myocardium that has
undergone hypertrophy and has onset of early dysfunction.
By examining all the protein changes globally for those
that underwent significant change in expression, we sought
to uncover novel proteins that may provide mechanistic
clues in this pathophysiology and potentially yield molecu-
lar targets that may attenuate the deleterious effects.
MATERIAL AND METHODS
Animal Preparation
All animals received humane care in compliance with the ‘‘Guide for the
Care and Use of Laboratory Animals’’ prepared by the National Academy
of Sciences and published by the National Institutes of Health, revised in
1996. The experimental protocols for the individual studies were approved
by Duke University’s Institutional Animal Care and Use Committee.
Twelve Yorkshire 1-week-old piglets (weighing 2.5–3.0 kg) were ran-
domized to pulmonary artery banding (PAB group) or a sham operation
consisting of thoracotomy alone to serve as controls. Piglets were sedated
with intramuscular acepromazine (1.1 mg/kg), followed by intravenous ket-
amine (22 mg/kg) administered via a cannula inserted into the marginal vein
of the ear. Orotracheal intubation was performed with a 3.0-mm endotra-
cheal tube and ventilation administered (BIRD 8400ST Ventilator, Bird
Products Corp, Palm Springs, Calif) at 25 breaths/min, tidal volume 50
mL, with isoflurane administered at 2% and oxygen at 40%, adjusted ap-
propriately to maintain blood oxygen saturations at more than 97%. Elec-
trocardiogram, blood oxygen saturations, rectal temperature, and end-tidal
carbon dioxide were all monitored.
PAB
Through a left lateral thoracotomy, three micromanometer catheters
(Millar Instruments, Inc, Houston, Tex) were sited: into the RV cavity
through the RV wall, directly into proximal pulmonary artery (PA), and
into the aorta. Baseline measurements were made. The PA catheter was ad-
vanced back and forth to confirm absence of congenital PA stenoses.The Journal of Thoracic and CaTwo-millimeter cotton umbilical tape was passed around the PA and
twisted gradually to achieve controlled banding, while monitoring RV
and proximal PA pressures. At signs of RV distress (electrocardiographic
changes, bradycardia, dusky or distended RV, hemodynamic instability)
the banding was halted and, if necessary, the band was loosened slightly
to allow recovery. When stable, the band was ligated with silk suture. In
this way, approximately a 30% to 50% reduction in cross-sectional area
could be achieved. After circulatory stabilization, hemodynamic measure-
ments were repeated, including PA pressures both proximal and distal to
the PAB. Sham-operated animals underwent PA dissection without banding.
The thoracotomy was closed with polydioxanone suture and bupivacaine
(0.25% 2 mL/kg) was administered locally to the wound. Postoperative
analgesia and broad-spectrum antibiotics were administered for 48 hours.
Animals were housed in a caged facility with full access to milk feed and
water.
Magnetic Resonance Imaging (MRI) Assessment
At 4 weeks, animals were anesthetized and intubated as described above,
maintained on isoflurane 2%, and studied supine on a clinical 1.5-T Mag-
netom Sonata, Siemens Medical scanner (Siemens Medical Solutions,
Erlangen, Germany). A phased-array receiver coil was employed. Electro-
cardiogram-gated gradient-echo MRIs encompassing the entire RV were ac-
quired during repeated breath-holds (6–10 seconds) to examine wall
motion, ventricular size, function, and mass. Cine images were acquired
in 6 to 8 short-axis views and 4 to 6 long-axis views. Slice thickness (ST)
was 5 mm, repetition time (TR) ranged from 29.25 to 31.77 ms, echo
time (TE) ranged from 1.6 to 1.8 ms, field of view (FOV) ranged from
250 to 300 mm, flip angle (FA) equaled 85, and the matrix was 120 3
256 or 144 3 256 pixels. Multislice half-Fourier acquisition single-shot
turbo spin-echo (HASTE) sequences were performed in axial, sagittal,
and coronal planes to further delineate PA anatomy (ST ¼ 4 mm, TR
400–900 ms, TE ¼ 22 ms, FOV 200–300 mm, FA ¼ 160, matrix 144 3
192). Retrospectively gated velocity-encoded phase contrast sequences
with 25 reconstructed frames per cardiac cycle were performed for quanti-
fication of peak velocity at the level of the PA (ST ¼ 5.5 mm, velocity en-
coding ranged from 50–300, TR¼ 78 ms, TE¼ 4 ms, FOV 142.5–240 mm,
FA 20–25, matrix 152 3 256 pixels). Late gadolinium imaging was
performed in the short-axis views with the use of a single-shot inversion
recovery sequence at 10 minutes after injection of 0.3 mmol/kg intravenous
gadolinium–diethylenetriaminepentaacetic acid (DTPA; Magnevist, Sher-
ing Oy, Helsinki, Finland) (ST 5–6 mm, inversion time ranged from 350–
400 ms, TR 750–1000 ms, TE 1.43–1.49, FOV 180–200 mm, FA ¼ 50,
matrix 144 3 192 or 160 3 192) to assess myocardial scarring.
MRI data were analyzed with commercially available dedicated software
(Leonardo; Siemens Medical Systems). Endocardial and epicardial borders
were manually traced in each short-axis slice at end-systole and end-dias-
tole. RV free wall to the level of the pulmonary valve and trabeculations
on the RV side of the septum were included in RV mass measurements.
Measurements of the PAB site were taken from the axial and sagittal
HASTE images. The phase contrast velocity data across the PAB site
were analyzed with dedicated software (Argus; Siemens Medical Systems).
Images were analyzed by a reviewer blinded to the animal’s PAB status.
Qualitative assessment of RV hypertrophy and RV function was also
graded: none, mild, moderate, or severe.
Animal Harvest
Anesthetized and ventilated animals underwent median sternotomy. He-
modynamic measurements were repeated as described above. A reviewer
blinded to the animal’s PAB status made a subjective assessment for the
presence of ascites, pleural effusion, and peripheral edema (graded: none,
mild, moderate, severe). Animals were humanely killed with intravenous
potassium and the heart was rapidly excised. RV, LV, and interventricular
septa were harvested and weighed, and planimetry was performed to deter-
mine surface area. Tissue was then snap frozen in liquid nitrogen and storedrdiovascular Surgery c Volume 137, Number 5 1147
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DFIGURE 1. Development of significant increase in RV mass was found by both MRI and on autopsy in the PAB animals. MRI demonstrated a significant
decrease in RV ejection fraction (P< .05) and an increase in RV end-systolic volume (P ¼ .06) in response to PAB of 4 weeks.at80C. A random sample from the RV free wall was used for proteomic
analysis. The piglet livers were also excised and weighed.
Proteomics Analysis
Protein separation: 2-dimensional electrophoresis. Our
proteomic methodology has previously been described.5 In brief, 50 mg
of piglet RV free wall was homogenized in 1 mL of 25-mol/L 1,2-dihepta-
noyl-sn-glycero-3-phosphatidylcholine (DHPC) lysis buffer and subjected
to ultrasound sonication. Six gels were prepared from the purified protein
extracts. Each gel consisted of three samples run concurrently: one PAB ani
mal sample, one control animal sample, and an internal control. To create
the internal control, we pooled equivalent amounts of all samples in the
experiment. Labeling with the fluorescent cyanine dyes was as follows:
internal control—Cy2 (blue); control animal—Cy3 (green); experimental
animal—Cy5 (red). Total protein, 120 mg, from each sample was labeled
with 400 pmol/L of Cy dyes for 30 minutes at 4C in the dark. The labeling
reaction was stopped by adding 1-mL (10-mmol/L stock) lysine (Sigma Al-
drich, St Louis, Mo). The three samples (Cy2, Cy3, Cy5) to be run on a sin-
gle gel were then combined (250 mL) and applied to immobilized pH
gradient strips (13 cm, pI ranges 3–10, Immobiline DryStrip; GE Health-
care, Waukesha, Wis). For the first dimension, after active rehydration
(30 V for 14 hours), immobilized pH gradient strips underwent isoelectric
focusing using an Ettan IPGphor II (GE Healthcare) for a total of 28 kVh.
After equilibration with dithiothreitol followed by iodoacetamide, the
immobilized pH gradient strips were placed on 12% homogeneous poly-
acrylamide gels (4% stacking) for the second dimension. Each sodium
dodecylsulfate–polyacrylamide gel electrophoresis was run at 9 mA for
16 hours in a Hoefer SE-600 system (Hoefer, Inc, Holliston, Mass).
Gel scanning and statistical analysis. The Cy2, Cy3, and Cy5
components of each gel were scanned with mutually exclusive excitation/
emission wavelengths (Typhoon 9410 Variable Mode Imager; GE Health-
care). A visible protein stain, Coomassie Brilliant Blue G250 stain (Bio-Rad
Laboratories, Hercules, Calif) was applied to allow visual inspection of the
protein spots. DeCyder 5.0 (GE Healthcare) differential analysis software
was used for protein spot detection, quantitation, spot matching, and statis-
tical analysis. All gels were standardized with the internal control (Cy2) im-
ages. Statistical analysis was performed by the unpaired Student t test,
comparing the standardized volume of each gel spot in the PAB animals
against the corresponding spot in the sham-operated animals. A robotic
spot cutter (Ettan Spot Picker, GE Healthcare) excised 2-mm gel plugs
from the selected protein spots for mass spectrometic analysis.
Protein identification: Mass spectrometry (MS). The
identity of the proteins in the selected spots was determined by mass spec-
trometry (MS). Matrix-assisted laser desorption/ionization (MALDI) time
of flight (TOF) MS was performed in conjunction with tandem MS (MS/1148 The Journal of Thoracic and Cardiovascular SMS; UNC–Duke Michael Hooker Proteomics Core Facility, University of
North Carolina, Chapel Hill, NC). In brief, MALDI–MS and MALDI–
MS/MS data were acquired with an ABI Voyager 4700 MALDI–TOF/
TOF mass spectrometer (Applied Biosystems Inc, Foster City, Calif). The
8 most intense peaks with a signal-to-noise ratio greater than 25 were se-
lected automatically for MS/MS analysis. The peptide mass fingerprinting
and sequence tag data from the TOF/TOF were evaluated with GPS Ex-
plorer scores. MS/MS spectra were submitted to the National Center for
Biotechnology Information database to generate ion scores via the Mascot
search engine (Matrix Science, Inc, Boston, Mass).7
Statistical Analysis
Perioperative variables were analyzed by repeated-measures analysis of
variance and paired and unpaired Student t tests, as appropriate. Qualitative
assessments of RV hypertrophy, RV function, and presence of ascites and
pleural effusion were compared betweens groups by the 2-tailed Fisher’s
exact test. For proteomic analysis, statistical analysis was performed with
DeCyder 5.0 software as described earlier.
RESULTS
PAB
There were no operative deaths. RV mean ejection pres-
sure and mean PA pressures were similar in both PAB
animals and sham-operated animals before banding. An
immediate 64% increase in mean RV ejection pressure
was achieved with banding (44  7 vs 27  4 mm Hg, post-
banding vs prebanding pressures; P< .001); mean PA pres-
sure increased 56% proximal to the band (28 5 mm Hg vs
18.5 4 mm Hg; P<.05). A mean pressure gradient of 13
8 mm Hg was produced across the band.
MRI Assessment
In vivo MRI assessment demonstrated RV free wall of
PAB animals to be of greater thickness (6.28  0.7 mm vs
3.58  0.9 mm; P< .001) and of greater mass (16  5.2 g
vs 9.9  2.0 g; P< .05; see Figure 1). RV end-systolic vol-
ume was also increased (10.6  3 mL vs 7.5  1.9 mL con-
trols, P ¼ .06), although end-diastolic volumes were similar
(17.7  3.2 mL vs 17.1  3 mL controls). RV ejection
fraction was significantly reduced in PAB animals (39.8%urgery c May 2009
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D 15% vs 56.7%  10%; P< .05). The narrowest PA
diameter (mean) identified in the sham-operated group was
9.4  3.0 mm and 4.1  0.7 mm in the PAB animals (cor-
responding to the band; P < .001), which resulted in
a mean gradient of 17.4  11 mm Hg across the stenosis.
Blinded qualitative assessment for hypertrophy graded RV
hypertrophy as moderate in 5 PAB animals and severe in
the sixth. All control animals had no RV hypertrophy (P<
.005); for RV function, mild impairment was identified in
4 PAB animals and normal function in 2, with normal func-
tion seen in all control animals (P ¼ .06). No myocardial
scarring was seen in either group.
Harvest Data
At 4 weeks, there was no difference in body weight bet-
ween the groups, which were normal for age (PAB 9.5 
0.97 vs 10.1 0.88 kg; P¼ not significant). No animals ex-
hibited peripheral edema. In vivo assessment demonstrated
a 22 3 mm Hg gradient across the PAB. Mean RV ejection
pressure was significantly higher in PAB animals (36 3 vs
19  3.6 mm Hg; P< .0001). RV free wall was of greater
mass and thickness than in the control animals (RV mass:
18.5  3 vs 13  0.6 g controls; P< .005; RV thickness:
8  1 vs 5.3  0.7 mm controls; P< .001). Interventricular
thickness was also significantly increased, as was interven-
tricular mass when standardized for body weight. LV mass
was similar in both groups. By planimetry, RV free wall sur-
face area was found to be significantly increased in the PAB
animals (28  1.5 vs 25  2.6 cm2; P<.05). Qualitative as-
sessment of ascites graded 5 of the PAB animals to have
mild ascites, whereas none was noted in the sham-operated
group (P< .05 Fisher’s exact test). There was no difference
between the groups for pleural effusion, nor for liver weight
standardized to body weight (liver/body mass percent: PAB
3.44  0.30 vs 3.47  0.58; P ¼ not significant).
RV Myocardium Proteomic Analysis
Twenty-five protein spots were found to have statistically
significant differential expression (P<.05), with a further 2
spots of borderline significance (P ¼ .057, .059). A repre-
sentative gel image is shown in Figure 2. All protein spots
were successfully identified by MS/MS (Table 1). These
27 spots were found to represent 18 proteins, which we
have classified into structural proteins, metabolic enzymes,
heat shock proteins (HSPs), and miscellaneous. The struc-
tural proteins, vinculin (2 spots), tropomyosin b chain,
tropomyosin 1 a chain (3 spots), LIM domain protein
CLP-36 and calsarcin-1 (2 spots) all showed increased dif-
ferential expression in the PAB group, ranging from 46%
to 136%. Metabolic enzymes, enolase a, cytoplasmic ma-
late dehydrogenase (2 spots), medium chain acyl-CoA dehy-
drogenase chain A, superoxide dismutase, and ubiquinol
cytochrome c reductase cytochrome c1 (2 spots) showedThe Journal of Thoracic and Caincreased expression (ranging from 34%–75%), whereas
F1-ATPase b-chain (2 spots) showed a reduction (33%), in
PAB animals. Of the HSPs, a-b crystallin increased expres-
sion by 111%, and HSP-70 decreased expression by 29%.
Observed molecular weights were also calculated by De-
Cyder software for the significant protein spots. Both vincu-
lin spots had slightly lower molecular weights than the
parent protein (90.6 and 90.2 kDa vs theoretical 116.8
kDa), suggesting the parent protein had undergone some
form of cleavage. Other structural protein spots had ob-
served molecular weights similar to those of their parent pro-
teins (with theoretical molecular weights from protein
databases): calsarcin-1 (2 spots) 33.6 and 33.2 kDa (29.7
kDa); LIM domain protein CLP-36 38.1 kDa (35.6 kDa);
tropomyosin a chain (3 spots) 38.1, 32.7, 36.2 kDa (32.6
kDa); tropomyosin b chain 39.2 kDa (32.8 kDa). The meta-
bolic enzymes also showed similar molecular weights to
FIGURE 2. Example of 2-dimensional differential gel electrophoresis of
RV myocardium. The Cy2 (internal control) image is shown including iden-
tification numbers for the protein spots of interest. A typical 3-dimensional
representation of a protein gel spot, as analyzed and displayed by DeCyder
software, is shown below the gel, taking F1-ATPase b-chain (spot 1063) as
an example. The Cy3 (sham) protein image is on the left and the Cy5 (PAB)
image on the right. It can be seen there is a decrease of F1-ATPase b-chain
peptide in the PAB animal.rdiovascular Surgery c Volume 137, Number 5 1149
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DTABLE 1. Right ventricular myocardium proteomics analysis
Gel spot number Protein identification Protein accession number* Average ratio changey Percent changez
Structural proteins
456 Vinculin AAL50327 1.51  0.31 þ51%
460 Vinculin AAL50327 1.46  0.32 þ46%
1328 Tropomyosin b-chain S00922 2.36  0.41 þ136%
1348 Tropomyosin 1 a-chain S24972 2.42  0.43 þ142%
1391 Tropomyosin 1 a-chain S24972 2.29  0.44 þ129%
1398 Tropomyosin 1 a-chain S24972 1.89  0.40 þ89%
1359 LIM domain protein CLP-36 Q6IN45 1.65  0.37 þ65%
1451 Calsarcin-1 Q9JJW5 1.87  0.42 þ87%
1461 Calsarcin-1 Q9JJW5 1.71  0.39 þ71%
Metabolic enzymes
1063 F1-ATPase, b-chain 1MABB 1.5  0.31 33%
1070 F1-ATPase, b-chain 1MABB 1.53  0.19 35%
1089 Enolase a A29170 1.45  0.35 þ45%
1222 Medium chain acyl-CoA dehydrogenase,
chain A
3MDDA 1.38  0.30 þ38%
1403 Malate dehydrogenase, cytoplasmic AAA31072 1.75  0.35 þ75%
1427 Malate dehydrogenase, cytoplasmic AAA31072 1.46  0.32 þ46%
1514 Ubiquinol-cytochrome-c reductase
cytochrome c1
CCBO1 1.46  0.36 þ46%
1537 Ubiquinol-cytochrome-c reductase
cytochrome c1
CCBO2 1.34  0.33 þ34%
1781 Superoxide dismutase [precursor] AAB60902 1.66  0.39 þ66%
Heat shock proteins
1794 a-b crystallin JC5971 2.11  0.55 þ111%
838 Heat shock 70 kDa protein 1 Q8WNS9 1.4  0.30 29%
Miscellaneous proteins
1520 TPM4-ALK fusion oncoprotein type
2 [fragment]
AAG17014 1.62  0.30 þ62%
1574 Proteasome activator 28-a subunit AAQ83574 1.47  0.35 þ47%
1581 Adenylate kinase 2 (theoretical) Q8C7I9 1.42  0.32 þ42%
899 ASPM protein [fragment] AAR98744 1.66  0.30 40%
935 ASPM protein [fragment] AAR98742 1.4  0.28 29%
688 ASPM protein [fragment] AAR98744 1.36  0.22 26%
1292 ASPM protein [fragment] AAS48533 1.33  0.30 þ33%
Protein spots depicted were statistically significant by the Student unpaired t test (P<.05) comparing PAB protein spot volumes to corresponding control spot volumes after stan-
dardization to the internal control (except malate dehydrogenase, spot 1427, P¼ .059, and superoxide dismutase, spot 1781, P¼ .057). *The protein accession number is obtained
from public databases, such as Protein Information Resource (http://pir.georgetown.edu/) or Swissprot (http://us.expasy.org). yAverage ratio change, also known as fold change,
calculated by DeCyder, are given as mean  SE. Values are displayed in the range ofN to1 for decreases in expression andþ1 toþN for increases in expression (no values
between1 andþ1). Therefore, a ratio of 2.0 is a 2-fold increase,2.0 is a 2-fold decrease. zThe average ratio change has been converted into percentage change. For a positive ratio
change of x this is calculated as (x1) $ 100 to give percentage increase; for a negative ratio change of x, this is calculated as [1(1/x)] $ 100 to give the percentage decrease. RV,
Right ventricular; ASPM, abnormal spindle-like microcephaly-associated protein; PAB, pulmonary artery band.predicted: F1-ATPase b-chain (2 spots) 53.7 and 53.7 kDa
(49 kDa); a enolase 52.9 kDa (47.1 kDa); medium chain
acyl-CoA dehydrogenase 44.4 kDa (42.3 kDa); cytoplasmic
malate dehydrogenase (2 spots) both 36 kDa (31.7 kDa);
ubiquinol–cytochrome-c reductase (2 spots) 30.7 and 29.5
kDa (27.3 kDa). HSPs had similar molecular weights to pre-
dicted: a-b crystallin 20.1 kDa (20.1 kDa); HSP-70 70 kDa
(69.9 kDa). Of the miscellaneous proteins, we found 4 spots
representing 2 different fragments of a very large parent pro-
tein, abnormal spindle-like microcephaly associated protein,
theoretical molecular weight 395 kDa): 3 spots (accession
number: AAR98742) had molecular weights of 63.6, 61.6,
and 76.8 kDa, all showed a fall in expression with PAB of1150 The Journal of Thoracic and Cardiovascular S32%; 1 spot (accession number: AAS48533) had a molecu-
lar weight of 41.3 kDa and showed an increase of 33% in
expression. Remaining miscellaneous proteins had similar
molecular weights to those predicted of their parent proteins:
TPM4-ALK fusion oncoprotein 30.4 kDa (27.5 kDa); pro-
teasome activator 28-a subunit 27.7 kDa (28.6 kDa).
DISCUSSION
Ventricular hypertrophy with subsequent dysfunction has
been the subject of extensive study. The molecular mecha-
nisms that underlie the change from a compensated to de-
compensated state remain elusive. The RV has, however,
been relatively neglected and most research has focusedurgery c May 2009
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Don the LV. Although the significant protein changes that
mediate the decompensation may be the same for both LV
and RV myocardium, this is not necessarily so.
We have developed a neonatal large animal model in
which aggressive RV pressure overload induces RV hyper-
trophy. Mild RV systolic functional impairment was demon-
strated, using MRI, qualitatively and quantitatively by
a decrease in RV ejection fraction. Mild RV cavity dilatation
was also found, with increased RV end-systolic dimension
on MRI and increased RV surface area by planimetry. Fea-
tures of overt RV failure, such as edema, hepatomegaly,
marked RV dilatation, and RV myocardial scarring, were
not seen. A greater degree of ascites was found in the
PAB animals. We conclude that the model is demonstrating
RV hypertrophy with early systolic dysfunction and infer
that this may be the point at which RV hypertrophy is tran-
sitioning from adaptive to maladaptive. Undertaking
a proteomic approach, we identified proteins that undergo
significant expression change in neonatal hypertrophied
RV myocardium that is accompanied by mild systolic dys-
function.
The energetics of hypertrophy (LV) and heart failure have
been extensively studied. In heart failure, abnormalities are
found in myocardium relating to substrate use, oxidative
phosphorylation, and the high energy transfer mechanism
involving creatine.8 We found an increase in several meta-
bolic enzymes, but a decrease in the b-chain of the F1 sub-
unit of ATP synthase. F1F0-ATP synthase complex
converts ADP to ATP through linkage to the electron trans-
port chain.9 The F1 sector comprises multiple subunit
proteins (a3b3gde). The b subunits provide the nucleotide-
binding catalytic sites.
Intriguingly, HSP-70 is also essential for mitochondrial
translocation and assembly of F1-ATPase.
10,11 HSP-70,
has been well documented in terms of its cytoprotective ef-
fects both in vitro and in vivo.12 We found a fall in HSP-70
expression. Sakamoto and associates13 have demonstrated
gene upregulation of HSP-70 and its regulatory factor,
heat shock transcription factor-1 (HSF-1), and increased
HSP-70 and HSF-1 protein expression in a mice model
of exercise-induced adaptive cardiac hypertrophy. These
were not found in mice ventricles where maladaptive hyper-
trophy, demonstrated using in vivo echocardiography, was
induced by pressure overload. Transgenic mice overexpress-
ing the HSF-1 gene that increased HSP-70 levels amelio-
rated the decline in ventricular function seen with chronic
pressure loading. Further studies are warranted to determine
whether the changes we have found in F1-ATPase b-chain
and HSP-70 may represent an early defect in energy metab-
olism with the onset of contractile dysfunction.
Calcineurin overactivity is widely known to induce car-
diac hypertrophy that progresses to failure14 Of the structural
proteins we identified, calsarcins are a family of sarcomeric
proteins that bind calcineurin, a calcium–calmodulin depen-The Journal of Thoracic and Cdent phosphatase, to a-actinin at the z-line.15 Frey and
colleagues16 have demonstrated that calsarcin-1 negatively
modulates calcineurin activity. Defects in cytoskeletal
proteins are increasingly being implicated in various cardio-
myopathies. Mutations in the gene for vinculin, a mem-
brane-associated cytoskeletal protein, are associated with
both dilated cardiomyopathy and hypertrophic cardiomyop-
athy phenotypes.17,18 Mechanical overload of the heart leads
to upregulation of vinculin.19 Failing human hearts have
been found to have increased vinculin levels.20
There have been two proteomic studies in mice that have
examined the protein changes in the RV with pressure over-
load. Faber and associates2 banded the PA of 8-week-old
mice and allowed them to survive for 6 weeks to produce
compensated RV hypertrophy, as determined by hemody-
namic assessment. There was some overlap with our find-
ings. There was an increase in several metabolic enzymes
and aB crystallin in PA-banded mice and a decrease in
ATP synthase d-chain. Aside from using a neonatal model
in swine, our results may also differ from these studies be-
cause, most significantly, our model gives rise to dysfunc-
tion as well as hypertrophy of the RV. Schott and
colleagues3 used 6-week-old mice and induced RV hyper-
trophy by injecting them with monocrotaline, an agent that
induces obliterative lung vasculitis and subsequent pulmo-
nary hypertension. Mice were allowed to survive for 3 weeks
with the model giving rise to compensated RV hypertrophy.
Their protein findings are significantly at odds with our work
as well as that of Faber and associates.2 Of the 14 proteins
they identified, 13 showed a decrease in the hypertrophied
RVs including tropomysosin, several metabolic enzymes,
and HSP-27. We infer that the monocrotaline model results
in profound biochemical and pathologic changes in excess
of simple pressure overload of the RV, and interpretation
of their results is exceedingly difficult.
We have sought to generate a reproducible model of RV
hypertrophy that leads to RV dysfunction, which we believe
is a significant advantage of our model. The early systolic
dysfunction and early RV cavity dilatation may represent
the onset of RV myocardial decompensation. We used ag-
gressive PAB to this end. The physiologic effects are partic-
ularly analogous to surgical PAB in neonatal babies, which
is undertaken as a temporizing measure for certain congen-
ital cardiac defects when definitive correction is not immedi-
ately possible. Congenital defects that, per se, give rise to
RV pressure overload, do so in a graduated and chronic fash-
ion, and the molecular basis of the accompanying RV hyper-
trophy and its dysfunction may not be quite the same.
Traditionally, scientific research entails surmising a hy-
pothesis and testing it. However, current knowledge will
limit hypothesis postulation. The strength of our molecular
analysis lies in that we have not presupposed for any partic-
ular proteins. By examining globally for changes in protein
profile, proteomics offers the possibility of uncovering novelardiovascular Surgery c Volume 137, Number 5 1151
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Dproteins. A highly sensitive technique, it also has the poten-
tial to highlight changes in specific peptides that comprise
a particular protein. Protein identification is based on com-
paring the data from the mass spectrometric analysis (peptide
mass fingerprint and peptide sequencing) to theoretical data-
bases, where the protein properties are derived from genomic
databases. Proteomic analysis, therefore, can also uncover
proteins that have never been characterized, but the existence
of which is inferred from the genome.5
Our study highlights a number of proteins that may war-
rant further investigation in understanding the pathogenesis
of RV hypertrophy with dysfunction. Further work could
also examine the role of these proteins as biomarkers of ei-
ther RV myocardial hypertrophy or dysfunction, or both.
There are several limitations in our study. We were unable
to obtain load-independent indices of RV function by attain-
ing pressure–volume measurements under different loading
conditions. Sonomicrometry21 or pressure conductance22,23
could be used for this purpose, although both have greater
limitations in RV analysis compared with the LV, on ac-
count of the complex geometry of the RV. The use of sono-
micrometry for this purpose was precluded by the extremely
dense scar tissue reaction encountered in the swine at the
time of harvest, making safe dissection of the heart to apply
the ultrasonic crystals perilous. Furthermore, the scar tissue
around the PA also prevented us from dissecting and releas-
ing the PAB in vivo, while hemodynamic assessment was
undertaken.
There are also important limitations of the proteomics
analysis. First, we chose to analyze a random portion of
the RV free wall without isolating myocytes specifically.
As such, interstitial cells, such as fibroblasts, and extracellu-
lar matrix would be included in the proteomic analysis.
Important protein changes may indeed occur in the non-
myocyte component of the RV in the pathophysiology of
RV hypertrophy and dysfunction, and such changes have
been demonstrated in maladaptive hypertrophy of the
LV.24 From our current work, we cannot localize the protein
changes to a particular cell type. This could be delineated
using co-localization studies, such as immunolocalization.
The proteomic analysis demonstrates ratio change of
a particular protein to that of the total protein milieu of RV
cells. For example, we found a 2.11-fold increase in expres-
sion of a-b crystalline in the PAB group, indicating that the
ratio of a-b crystalline to the total protein content of the RV
myocardium was more than twice that of the controls. How-
ever, the nature of the exact change in expression of the iden-
tified protein has not been demonstrated. An increase in
expression may reflect an increase in de novo synthesis or
an increase in a particular isoform resulting from some post-
translational modification, for example, phosphorylation,
ubiquination, or glycosylation. Further work is necessary
to delineate the nature of the expression changes in the pro-
teins we have found.1152 The Journal of Thoracic and Cardiovascular SProteomic analysis is also limited in that cause and effect
cannot be delineated. As such, it is limited in determining
pathophysiologic mechanisms by itself. Which proteins
are beneficial, harmful, or are bystanders in this model has
not been determined. However, where a mechanism is
known, but the details are incomplete, a focused proteomic
analysis, where a discrete subproteome is examined, can
help. This approach was demonstrated well by Ping and col-
leagues,25 who used protein kinase Ce monoclonal anti-
bodies to immunoprecipitate proteins involved in protein
kinase Ce downstream signaling. The precipitated proteins
were identified by 2-dimensional electrophoresis followed
by MALDI MS. This proteomic approach uncovered a num-
ber of novel protein kinase Ce protein targets in ischemic
preconditioning. In our current study, a spectrum of proteins
has been identified from structural and cytoskeletal proteins
to those involved in myocyte energetics. Further studies are
required to delineate the exact roles these proteins play in the
pathogenic pathway. The purpose of this pilot work has been
to highlight or uncover proteins that warrant further investi-
gation.
We were satisfied from the consistency of results obtained
from the gel analysis and the mass spectrometric analysis
that we have unambiguously identified proteins undergoing
significant change in this model. Further strength could be
added to these findings by undertaking independent verifica-
tion of these protein changes using molecular techniques,
such as Western blotting. An alternative approach would
be to correlate these findings to the genomic changes, which
is additional work we are currently undertaking.
In summary, we have produced a neonatal model of RV
hypertrophy that is accompanied by early systolic dys-
function. With the use of proteomic techniques, we have
identified a number of proteins that accompany the pres-
sure-overloaded RV that shows RV hypertrophy and early
systolic functional impairment. The findings in this study
can guide further work to investigate the pathogenesis of
maladaptive RV hypertrophy.
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